Viatris balance sheet
At the end of fiscal 2025, Viatris had total assets of $37.19bn, total liabilities of $22.48bn and shareholders' equity of $14.71bn. It held $1.32bn in cash against $14.41bn of debt: net debt of $13.09bn.
Balance sheet
| Fiscal year | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.4 | 0.5 | 0.8 | 0.7 | 1.3 | 1.0 | 0.7 | 1.3 | 0.9 |
| Receivables | — | 3.1 | 4.8 | 4.3 | 3.8 | 3.7 | 3.2 | 3.0 | 3.1 |
| Inventory | — | 2.7 | 5.5 | 4.0 | 3.5 | 3.5 | 3.9 | 4.0 | 3.9 |
| Total current assets | — | 6.8 | 12.9 | 10.9 | 10.6 | 13.0 | 9.5 | 9.8 | 10.1 |
| Goodwill | 9.7 | 9.6 | 12.3 | 12.1 | 10.4 | 9.9 | 9.1 | 6.8 | 6.7 |
| Total assets | — | 31.3 | 61.6 | 54.8 | 50.0 | 47.7 | 41.5 | 37.2 | 35.0 |
| Total current liabilities | — | 5.6 | 10.6 | 9.9 | 6.7 | 7.8 | 5.8 | 7.1 | 6.3 |
| Short-term debt | — | 1.5 | 2.3 | 1.9 | 1.3 | 1.9 | 0.0 | 1.9 | 1.7 |
| Long-term debt | — | 11.2 | 22.4 | 19.7 | 18.0 | 16.2 | 14.0 | 12.5 | 11.6 |
| Total debt | 0.0 | 12.7 | 25.8 | 23.1 | 19.3 | 18.1 | 14.0 | 14.4 | 13.4 |
| Total liabilities | — | 19.4 | 38.6 | 34.4 | 28.9 | 27.2 | 22.9 | 22.5 | 20.8 |
| Shareholders' equity | 12.2 | 0.0 | 23.0 | 20.5 | 21.1 | 20.5 | 18.6 | 14.7 | 14.3 |
| Non-controlling interests and other (assets − liabilities − equity) | — | 11.9 | — | — | — | — | — | — | — |
| Net debt (negative = net cash) | −0.4 | 12.2 | 25.0 | 22.4 | 18.0 | 17.1 | 13.3 | 13.1 | 12.5 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 3.7 | 3.2 | 3.1 | 3.3 | 3.4 | 3.0 | 3.1 | 3.1 |
| Inventory | 4.1 | 3.9 | 4.1 | 4.3 | 4.1 | 4.0 | 3.9 | 3.9 |
| Total current assets | 11.3 | 9.5 | 9.6 | 9.8 | 10.0 | 9.8 | 10.9 | 10.1 |
| Goodwill | 9.6 | 9.1 | 6.5 | 6.7 | 6.7 | 6.8 | 6.7 | 6.7 |
| Total assets | 44.8 | 41.5 | 38.5 | 38.4 | 37.9 | 37.2 | 36.8 | 35.0 |
| Total current liabilities | 7.5 | 5.8 | 5.7 | 7.1 | 7.4 | 7.1 | 6.8 | 6.3 |
| Short-term debt | 1.4 | 0.0 | 0.0 | 1.7 | 1.9 | 1.9 | 1.9 | 1.7 |
| Long-term debt | 14.3 | 14.0 | 14.2 | 12.8 | 12.5 | 12.5 | 12.4 | 11.6 |
| Total debt | 15.7 | 14.0 | 14.2 | 14.5 | 14.4 | 14.4 | 14.3 | 13.3 |
| Total liabilities | 25.0 | 22.9 | 22.8 | 22.8 | 22.7 | 22.5 | 22.2 | 20.8 |
| Shareholders' equity | 19.8 | 18.6 | 15.7 | 15.6 | 15.2 | 14.7 | 14.7 | 14.3 |
Compare with peers
- Haleon plc balance sheet
- Universe Pharmaceuticals Inc balance sheet
- Bausch Health Companies Inc. balance sheet
- Zoetis balance sheet
- Organon & Co. balance sheet
Head to head: HLN vs VTRSUPC vs VTRSBHC vs VTRSVTRS vs ZTS
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies